O3R-5671 is designed to overcome the limitations of first-generation SIK inhibitors, providing a potential new oral treatment option for multiple autoimmune diseases
Clinical Trial Application approval…Read More
You might also be interested in reading Abeona Therapeutics added to U.S. Small-cap Russell 2000 and Russell 3000 Indexes.